

Simone Saibeni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/324005/simone-saibeni-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83
papers

2,500
citations

28
h-index

48
g-index

97
ext. papers

2,897
ext. citations

3.8
avg, IF

4.54
L-index

#	Paper	IF	Citations
83	Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study. <i>American Journal of Gastroenterology</i> , 2021 , 116, 306-310	0.7	14
82	Insights into the role of gastrointestinal ultrasound in ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211051456	4.7	0
81	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1432-1441	6.1	1
80	Improvement in appropriateness and diagnostic yield of fast-track endoscopy during the COVID-19 pandemic in Northern Italy. <i>Endoscopy</i> , 2021 , 53, 162-165	3.4	4
79	Impact of COVID-19 Outbreak on the Management of Patients With Severe IBD: A Domino Effect. <i>Gastroenterology</i> , 2021 , 160, 2196-2197	13.3	4
78	Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. <i>Gut</i> , 2021 , 70, 623-624	19.2	31
77	Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology-Surgery Team to Include an Infectious Disease Specialist. <i>Gastroenterology</i> , 2021 , 160, 2625-2626	13.3	2
76	Inflammatory bowel disease in a colorectal cancer screening population: Diagnosis and follow-up. <i>Digestive and Liver Disease</i> , 2021 , 53, 587-591	3.3	1
75	Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. <i>United European Gastroenterology Journal</i> , 2021 , 9, 102-109	5.3	2
74	Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. <i>Digestive and Liver Disease</i> , 2021 , 53, 263-270	3.3	9
73	Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3050-3055	4	6
72	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020 , 69, 1213-1217	19.2	208
71	Efficacy of a novel self-assembling peptide hemostatic gel as rescue therapy for refractory acute gastrointestinal bleeding. <i>Endoscopy</i> , 2020 , 52, 773-779	3.4	17
70	Efficacy, safety and tolerability, the imperfect triangle arising from the new low volume colon preparations. <i>Digestive and Liver Disease</i> , 2020 , 52, 840-841	3.3	0
69	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e134-e136	4.5	2
68	Planning phase two for endoscopic units in Northern Italy after the COVID-19 lockdown: An exit strategy with a lot of critical issues and a few opportunities. <i>Digestive and Liver Disease</i> , 2020 , 52, 823-828	3.3	8
67	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1228-1235	5.3	8

66	Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e107-e109	4.5	5
65	Proposal for returning to routine endoscopy during the COVID-19 pandemic: what is really feasible?. <i>Endoscopy</i> , 2020 , 52, 815	3.4	2
64	Efficacy of withdrawal time monitoring in adenoma detection with or without the aid of a full-spectrum scope. <i>Endoscopy International Open</i> , 2019 , 7, E1135-E1142	3	1
63	Comparison of asymmetric (low morning-dose) and standard split-dose regimen of PEG plus bisacodyl for bowel preparation: A randomized controlled trial. <i>Digestive and Liver Disease</i> , 2019 , 51, 837-842	3.3	1
62	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , 2019 , 1, 93-99	1	2
61	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019 , 51, 632-639	3.3	22
60	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 568-579	4.5	35
59	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease TAGEDTstudy. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1361-1369	2.2	7
58	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2019 , 51, 212-217	3.3	5
57	A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 437-444	4.1	4
56	Endoscopy for patients affected by inflammatory bowel disease: bowel preparation and sedation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 119-124	4.2	2
55	Anti-tumour necrosis factor-antibodies and B cell homeostasis in human inflammatory bowel diseases. <i>International Immunopharmacology</i> , 2018 , 54, 329-335	5.8	4
54	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017 , 49, 338-358	3.3	34
53	Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 339-347	4.2	15
52	Aspecific ileitis: Crohn's disease or not Crohn's disease? A prospective study. <i>International Journal of Colorectal Disease</i> , 2017 , 32, 1025-1028	3	3
51	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 233-243	4.5	96
50	New horizons in the imaging of perianal Crohn's disease: transperineal ultrasonography. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 523-530	4.2	14
49	The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2017 , 49, 1092-1097	3.3	7

48	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. <i>Gastroenterology</i> , 2017 , 152, S108	13.3	2
47	The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 33-41	4.2	7
46	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017 , 49, 17-23	3.3	26
45	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilar. <i>Gastroenterology</i> , 2016 , 150, S92	13.3	5
44	Significance of serum IL-9 levels in inflammatory bowel disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2015 , 28, 569-75	3	22
43	How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey. <i>Digestive and Liver Disease</i> , 2015 , 47, 170-3	3.3	3
42	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014 , 46, 963-8	3.3	36
41	Fundic gland polyps and proton pump inhibitors: an obvious link, or an open question?. <i>Human Pathology</i> , 2014 , 45, 1122-3	3.7	7
40	Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 949-62	4.2	9
39	Morphological distribution of F-actin and cd15 receptors in colorectal polyp and adenocarcinoma specimens. <i>BMC Clinical Pathology</i> , 2013 , 13, 8	3	2
38	Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. <i>International Journal of Colorectal Disease</i> , 2013 , 28, 1281-6	3	
37	Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 202-10	12.3	104
36	Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1112-22	0.7	35
35	Unusual B cell morphology in inflammatory bowel disease. <i>Pathology Research and Practice</i> , 2012 , 208, 387-91	3.4	2
34	The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. <i>Digestive and Liver Disease</i> , 2012 , 44, 123-7	3.3	44
33	Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1006-10	4.5	89
32	Management of warfarin-associated coagulopathy in patients with acute gastrointestinal bleeding: a cross-sectional physician survey of current practice. <i>Digestive and Liver Disease</i> , 2011 , 43, 444-7	3.3	9
31	Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. <i>Journal of Hepatology</i> , 2011 , 55, 1241-8	13.4	65

30	B lymphocyte intestinal homing in inflammatory bowel disease. <i>BMC Immunology</i> , 2011 , 12, 71	3.7	15
29	Impact of gluten withdrawal on health-related quality of life in celiac subjects: an observational case-control study. <i>Digestion</i> , 2010 , 82, 221-8	3.6	23
28	Increased thrombin generation in inflammatory bowel diseases. <i>Thrombosis Research</i> , 2010 , 125, 278-82	8.2	52
27	Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 581-8	6.1	35
26	The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. <i>Digestive and Liver Disease</i> , 2008 , 40, 814-20	3.3	35
25	Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune responses to bacteria. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 812-8	4.5	30
24	Rapid blossoming of Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 453	4	
23	Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 542-9	4	60
22	A 15-Yr Prospective Histological Follow-Up Study in Patients With Persistently Normal Aminotransferase Levels (PNAL) Carrying HCV Infection. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2604-6	0.7	5
21	Angiotensin-converting enzyme insertion/deletion gene polymorphism in inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 976-81	2.2	10
20	Inflammation and coagulation in inflammatory bowel disease: The clot thickens. <i>American Journal of Gastroenterology</i> , 2007 , 102, 174-86	0.7	267
19	Imaging of the small bowel in Crohn's disease: a review of old and new techniques. <i>World Journal of Gastroenterology</i> , 2007 , 13, 3279-87	5.6	46
18	Hypokalemic rhabdomyolysis without watery diarrhea: an unexpected presentation of a pancreatic neuro-endocrine tumor. <i>American Journal of Gastroenterology</i> , 2006 , 101, 669-72	0.7	3
17	Response to Letter of Koutroubakis et al.. <i>American Journal of Gastroenterology</i> , 2006 , 101, 403-404	0.7	1
16	Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1510-6	15.4	22
15	Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 497-506	6.1	47
14	Prevalence of hyperhomocysteinemia in adult gluten-sensitive enteropathy at diagnosis: role of B12, folate, and genetics. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 574-80	6.9	65
13	Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 1243-5	2.2	21

12	Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn's ileal disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 557-64	6.1	16
11	Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 1129-38	6.1	57
10	Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2036-41	0.7	74
9	Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. <i>Hepato-Gastroenterology</i> , 2005 , 52, 509-15		16
8	Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1966-70	0.7	48
7	Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. <i>Critical Care Medicine</i> , 2004 , 32, S266-70	1.4	48
6	Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. <i>American Journal of Gastroenterology</i> , 2003 , 98, 112-7	0.7	121
5	Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2003 , 35, 862-8	3.3	32
4	Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2003 , 35, 32-6	3.3	18
3	Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. <i>Gut</i> , 2003 , 52, 1435-41	19.2	186
2	Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 637-43	4	28
1	Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. <i>Digestive Diseases and Sciences</i> , 2000 , 45, 1465-9	4	69